Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Anika Therapeutics (ANIK) Debt to Equity (2020 - 2022)

Anika Therapeutics (ANIK) has disclosed Debt to Equity for 7 consecutive years, with $0.02 as the latest value for Q2 2022.

  • On a quarterly basis, Debt to Equity fell 74.36% to $0.02 in Q2 2022 year-over-year; TTM through Jun 2022 was $0.02, a 74.36% decrease, with the full-year FY2021 number at $0.02, down 68.72% from a year prior.
  • Debt to Equity was $0.02 for Q2 2022 at Anika Therapeutics, roughly flat from $0.02 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of $0.17 in Q2 2020 to a low of $0.01 in Q3 2021.
  • A 3-year average of $0.06 and a median of $0.05 in 2020 define the central range for Debt to Equity.
  • Peak YoY movement for Debt to Equity: tumbled 66.07% in 2021, then plummeted 83.24% in 2022.
  • Anika Therapeutics' Debt to Equity stood at $0.05 in 2020, then crashed by 68.72% to $0.02 in 2021, then increased by 0.33% to $0.02 in 2022.
  • Per Business Quant, the three most recent readings for ANIK's Debt to Equity are $0.02 (Q2 2022), $0.02 (Q1 2022), and $0.02 (Q4 2021).